Absci vs 20/20 Biolabs
ABSI and AIDX side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABSI and AIDX compare
Absci is the larger company, worth 605 times as much as 20/20 Biolabs ($1.7B against $2.9M).
20/20 Biolabs grew revenue faster over the last twelve months (16.7% versus −47.2% for Absci).
20/20 Biolabs keeps more of each dollar of sales as profit, with a net margin of −183% compared with −8451% at Absci.
20/20 Biolabs scores higher on the StockData Score (6 against 5 for Absci), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABSI | AIDX |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $2.9M |
| Share price | $10.12 | $0.225 |
| Change, 1 year | 205% | – |
| Change, 5 years | −8.4% | – |
| Beta (5Y) | 2.22 | – |
| Employees | 140 | 14 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1168× | 1.4× (better) |
| P/B | 7.9× | 1.8× (better) |
| FCF yield | −6.5% | – |
| Fair value | – | $0.553 |
| Margin of safety | – | 59.3% |
| Growth | ||
| Revenue growth (TTM) | −47.2% | 16.7% (better) |
| Revenue growth, 5Y average | −10.1% | – |
| Profitability | ||
| Gross margin | – | 29.6% |
| Operating margin | −8812% | −163% (better) |
| Net margin | −8451% | −183% (better) |
| FCF margin | −7563% | – |
| Return on equity | −58.6% (better) | −239% |
| Return on invested capital | −242% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −2569.4× | −21.3× (better) |
| Current ratio | 9.64 (better) | 1.99 |
| Altman Z-score | 44.67 (better) | −8.83 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −6.3% | – |
| Shareholder yield | −6.3% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 88.3% | 4.2% |
| Held by insiders | 15.5% | 14.8% |
| Insider net buying, 12 months | $801K | – |
| Short interest, % of float | 24.7% | 0.52% |
Go deeper
- ABSI stock overview
- ABSI income statement
- ABSI valuation and score
- AIDX stock overview
- AIDX income statement
- AIDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.